Drugs Design and Process Chemistry: A Factuality Study of Recent Advance in Drug Delivery Systems – A Comprehensive Review

Year : 2025 | Volume : 15 | Issue : 01 | Page : 26 35
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Shashikant Maury,

  • Neha,

  1. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  2. Academic Head, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  3. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh, India
  4. Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur, Uttar Pradesh,

Abstract

Recent years have seen significant advances in drug design and process chemistry, mostly due to breakthroughs in drug delivery technologies. This study provides a thorough examination of current developments in drug delivery, emphasizing strategies that improve therapeutic efficacy, reduce adverse effects, and maximize pharmacokinetic profile. The effects of several strategies on drug stability, solubility, and bioavailability are examined, including controlled-release systems, targeted delivery methods, and nanoparticle-based delivery. This review also highlights the significance of green chemistry and sustainable practices while examining the function of process chemistry in scaling up drug manufacture to satisfy regulatory criteria. We analyze current trends, issues, and potential paths in the subject using a factual (flexible and factual) approach, offering a fundamental resource for scholars.

Keywords: Chemotherapy, tumor, nanoparticles, drug delivery, pharmacokinetic

[This article belongs to Research and Reviews : A Journal of Biotechnology ]

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Shashikant Maury, Neha. Drugs Design and Process Chemistry: A Factuality Study of Recent Advance in Drug Delivery Systems – A Comprehensive Review. Research and Reviews : A Journal of Biotechnology. 2025; 15(01):26-35.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Shashikant Maury, Neha. Drugs Design and Process Chemistry: A Factuality Study of Recent Advance in Drug Delivery Systems – A Comprehensive Review. Research and Reviews : A Journal of Biotechnology. 2025; 15(01):26-35. Available from: https://journals.stmjournals.com/rrjobt/article=2025/view=196651


References

1. Rayaprolu BM, Strawser JJ, Anyarambhatla G. Excipients in parenteral formulations: selection considerations and effective utilization with small molecules and biologics. Drug Dev Ind Pharm. 2018;44(10):1565–1571. doi: 10.1080/03639045.2018.1483392
2. Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021;5(9):951–967. doi: 10.1038/s41551-021-00698-w.
3. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol. 2021;12:618411. doi: 10.3389/fphar.2021.618411.
4. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135–146. doi: 10.1016/j.jconrel.2010.08.027.
5. Agrahari V. Novel drug delivery systems, devices, and fabrication methods. Drug Deliv Transl Res. 2018;8(2):303–306. doi: 10.1007/s13346-017-0459-3.
6. Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology. 2018;16:1–33. doi: 10.1186/s12951-018-0392-8.
7. Li X, Szewczuk MR, Malardier-Jugroot C. Folic acid-conjugated amphiphilic alternating copolymer as a new active tumor targeting drug delivery platform. Drug Des Devel Ther. 2016:4101–4110. doi: 10.2147/DDDT.S123386
8. Mehrdadi S. Drug delivery of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to target brain tumors. Adv Pharm Bull. 2022;13(3):512–520. doi: 10.34172/apb.2023.062.
9. Doytchinova I. Drug design—past, present, future. Molecules. 2022;27(5):1496. doi: 10.3390/molecules27051496.
10. Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239–1249. doi: 10.1111/j.1476-5381.2010.01127.x.
11. Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018;11:156–164. doi: 10.1016/j.conctc.2018.08.001.
12. Patton EE, Zon LI, Langenau DM. Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat Rev Drug Discov. 2021;20(8):611–628. doi: 10.1038/s41573-021-00210-8.
13. Cassar S, Adatto I, Freeman JL, Gamse JT, Iturria I, Lawrence C, et al. Use of zebrafish in drug discovery toxicology. Chem Res Toxicol. 2019;33(1):95–118. doi: 10.1021/acs.
chemrestox.9b00335.
14. MacRae CA, Peterson RT. Zebrafish as tools for drug discovery. Nat Rev Drug Discov. 2015;14(10):721–731. doi: 10.1038/nrd4627.
15. Guerra-Farfan E, Garcia-Sanchez Y, Jornet-Gibert M, Nuñez JH, Balaguer-Castro M, Madden K. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2023;54 Suppl 3:S26–S29. doi: 10.1016/j.injury.2022.01.047.
16. Cięszczyk N, Czech M, Pronicki Ł, Gujski M. Knowledge and beliefs about clinical trials among adults in Poland: A cross-sectional study. Clin Pract. 2024;14(4):1285–1295. doi: 10.3390/clinpract14040104.
17. Jose C, Amra K, Bhavsar C, Momin MM, Omri A. Polymeric lipid hybrid nanoparticles: Properties and therapeutic applications. Crit Rev Ther Drug Carrier Syst. 2018;35(6):555–588. doi: 10.1615/CritRevTherDrugCarrierSyst.2018024751.
18. Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79. doi: 10.1016/j.ejpb.2015.03.018.
19. Choudhury H, Gorain B, Pandey M, Khurana RK, Kesharwani P. Strategizing biodegradable polymeric nanoparticles to cross the biological barriers for cancer targeting. Int J Pharm. 2019;565:509–522. doi: 10.1016/j.ijpharm.2019.05.042.
20. Rizwanullah M, Alam M, Harshita, Mir SR, Rizvi MM, Amin S. Polymer-lipid hybrid nanoparticles: A next-generation nanocarrier for targeted treatment of solid tumors. Curr Pharm Des. 2020;26(11):1206–1215. doi: 10.2174/1381612826666200116150426.
21. Mohanty A, Uthaman S, Park IK. Utilization of polymer-lipid hybrid nanoparticles for targeted anti-cancer therapy. Molecules. 2020;25(19):4377. doi: 10.3390/molecules25194377.
22. Girelli AM, Astolfi ML, Scuto FR. Agro-industrial wastes as potential carriers for enzyme immobilization: A review. Chemosphere. 2020;244:125368. doi: 10.1016/j.chemosphere.
2019.125368.
23. Chandrasekhar SA, Satyanarayana KG, Pramada PN, Raghavan P, Gupta TN. Review processing, properties and applications of reactive silica from rice husk—An overview. J Mater Sci. 2003;38(15):3159–3168. doi: 10.1023/A:1025157114800.
24. Girelli AM, Scuto FR. Eggshell membrane as feedstock in enzyme immobilization. J Biotechnol. 2021;325:241–249. doi: 10.1016/j.jbiotec.2020.10.016.
25. Kessi E, Arias JL. Using natural waste material as a matrix for the immobilization of enzymes: Chicken eggshell membrane powder for β-galactosidase immobilization. Appl Biochem Biotechnol. 2019;187(1):101–115. doi: 10.1007/s12010-018-2805-4.

Regular Issue Subscription Review Article
Volume 15
Issue 01
Received 14/12/2024
Accepted 07/01/2025
Published 01/02/2025
Publication Time 49 Days
244

Login


My IP

PlumX Metrics